

Product Data Sheet

G3-C12 TFA

Cat. No.: HY-P1592A

Molecular Weight: 1873

Target: Galectin ANTPCGPYTHDCPVKR (TFA salt)

Pathway: Immunology/Inflammation

Storage: Sealed storage, away from moisture

Powder -80°C 2 years

-20°C 1 year

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro $H_2O : \ge 50 \text{ mg/mL} (26.70 \text{ mM})$

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	0.5339 mL	2.6695 mL	5.3390 mL
	5 mM	0.1068 mL	0.5339 mL	1.0678 mL
	10 mM	0.0534 mL	0.2670 mL	0.5339 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS

Solubility: 12.5 mg/mL (6.67 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description G3-C12 (TFA) is a galectin-3 binding peptide, with K_d of 88 nM, and shows anticancer activity.

IC₅₀ & Target Galectin-3

In Vitro

G3-C12 (TFA) is a galectin-3 binding peptide, with high affinity (K_d) of 88 nM, but shows no affinity for other galectin family members or to other lectins. G3-C12 (TFA) bearing opolymers N-(2-hydroxypropyl)methacrylamide (HPMA) potently and selectively targets colorectal cancer (CRC) tumour cells over-expressing galectin-3 and displays superior targetability to

galectin-3 compared to the galactose bearing copolymer [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

1]. Kopansky E, et al. Peptide-c	directed HPMA copolymer-dox	xorubicin conjugates as targete	d therapeutics for colorectal cancer. J Drug Target. 2011 Dec	:;19(10):933-43.
	Caution: Product has no	t been fully validated for m	edical applications. For research use only.	
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemExpress.com	
	Address: 11	Deer Park Dr, Suite Q, Monin	outh Junction, NJ 08852, USA	

Page 2 of 2 www.MedChemExpress.com